IL10 and colitis: In the colitis mice model, the treatment with MenSCs mainly regulated the response of B-lymphocytes, whereas the intravenous injection of MenSCs decreased the percentage of immature plasma cells in spleen and IgG deposition in colon but increased the secretion of IL-10 and the production of Bregs (CD19+IL-10+) [89].